Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Aprea Therapeutics, Inc. filed this Current Report on Form 8-K dated August 23, 2023, with the report signed August 24, 2023. The filing concerns board changes and matters submitted to stockholders at the 2023 annual meeting. Aprea’s common stock trades on Nasdaq under the symbol APRE.
Financial and Operating Metrics
The filing does not provide revenue, net income, cash flow, margins, debt, liquidity, or other financial performance metrics. It states that stockholders ratified EisnerAmper LLP as the independent registered public accounting firm for fiscal year 2023.
Material Changes
- Christian S. Schade resigned from the Board, including as Chairperson and from any board committees, effective August 23, 2023. The resignation was not due to disagreements with the Company regarding operations, policies, or practices.
- Richard Peters, M.D., Ph.D., was appointed Chairperson of the Board, effective immediately.
- Jean-Pierre Bizzari, M.D., was appointed as a Class III director, effective immediately, to serve until the 2025 annual meeting or earlier resignation or removal. He was not appointed to a board committee at the time of filing.
- Dr. Bizzari will participate in the Company’s non-employee director compensation arrangement. The filing reports no related-party transaction requiring disclosure, family relationship, or arrangement pursuant to which he was selected.
- At the August 23 annual meeting, stockholders elected Marc Duey, Richard Peters, and Bernd R. Seizinger as Class I directors, each to serve until the 2026 annual meeting or until a successor is elected and qualified.
Annual Meeting Results
| Item | Result |
|---|---|
| Shares entitled to vote | 3,731,571 |
| Shares represented at meeting | 2,147,072, or approximately 57.53% |
| Election of Class I directors | All three nominees elected |
| Auditor ratification | EisnerAmper LLP ratified for fiscal 2023 |
Votes for the director nominees were 1,564,552 for Marc Duey, 1,566,951 for Richard Peters, and 1,550,830 for Bernd R. Seizinger. The auditor ratification received 2,053,106 votes for, 81,077 against, and 12,889 abstentions, with no broker non-votes.
Guidance, Risks, and Unusual Items
The filing provides no financial guidance, outlook, operating risk update, contingencies, or unusual financial items. It identifies board leadership and director composition changes as the principal developments.
Investor Verification Points
- Confirm the effective dates and subsequent status of the board chair transition and Dr. Bizzari’s Class III appointment.
- Review the Company’s proxy statement for the detailed director compensation arrangement and annual meeting proposals.
- Verify fiscal 2023 financial results, liquidity, capital resources, and auditor’s reports in the Company’s periodic SEC filings, as this 8-K does not provide those figures.
- Monitor future filings for any committee appointments involving Dr. Bizzari or further changes in board composition.